Top Buy
| Security | Buy | Sell ▲ | Buy (1M) | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Canopy Growth Corp | 4 | 0 | 0 | 0 | €0.47 | €1.75 | 273.134% |
| QIAGEN NV | 9 | 0 | 0 | 0 | €40.47 | €47.44 | 17.223% |
| MorphoSys AG | 7 | 0 | 0 | 0 | €69.40 | €65.00 | -6.340% |
| Viatris Inc. | 1 | 0 | 0 | 0 | €10.22 | - | - |
| Perrigo Co. plc | 3 | 0 | 0 | 0 | €27.59 | €35.99 | 30.429% |
| Uniqure B.V. | 1 | 0 | 1 | 0 | €4.66 | - | - |
| Ascendis Ph.sp.adr 1 Dk 1 | 1 | 0 | 0 | 0 | €114.00 | €150.00 | 31.579% |
| Blueprint Medicines Corp | 2 | 0 | 1 | 0 | €97.10 | - | - |
| Hutchison China MediTech Ltd ADR | 5 | 0 | 0 | 0 | €19.00 | €45.10 | 137.342% |
| Medpace Holdings Inc | 9 | 0 | 3 | 0 | €361.90 | €421.61 | 16.498% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €157.30 | €184.76 | 17.457% |
| Neurocrine Bioscience | 29 | 0 | 8 | 0 | €131.30 | €140.60 | 7.086% |
| United Therapeutics | 18 | 0 | 3 | 0 | €250.60 | €288.66 | 15.188% |
| Exelixis Inc. | 18 | 0 | 3 | 0 | €19.53 | €26.01 | 33.161% |
| Alnylam Pharmace. | 36 | 0 | 2 | 0 | €139.25 | €236.30 | 69.693% |
| Halozyme Therapeutics Inc. | 14 | 0 | 2 | 0 | €41.76 | €50.33 | 20.528% |
| Amicus Therapeutics Inc. | 6 | 0 | 3 | 0 | €8.75 | €17.78 | 103.191% |
| Jazz Pharmaceuticals plc | 23 | 0 | 3 | 0 | €102.50 | €184.92 | 80.410% |
| Icon plc | 18 | 0 | 3 | 0 | €290.80 | €319.67 | 9.928% |
| Horizon Pharma plc | 6 | 0 | 0 | 0 | €110.40 | - | - |
| Agios Pharmaceuticals Inc. | 6 | 0 | 2 | 0 | €32.40 | €38.99 | 20.335% |
| Nektar Therapeutics | 3 | 1 | 0 | 0 | €1.59 | €3.70 | 132.704% |